Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Extended anticoagulation in venous thromboembolism.

Schulman S; RE-MEDY; RE-SONATE Trial Investigators.

N Engl J Med. 2013 Jun 13;368(24):2329. doi: 10.1056/NEJMc1304815. No abstract available.

2.

Extended anticoagulation in venous thromboembolism.

Edwards JL.

N Engl J Med. 2013 Jun 13;368(24):2329. doi: 10.1056/NEJMc1304815#SA3. No abstract available.

PMID:
23758243
3.

Extended anticoagulation in venous thromboembolism.

Hegerfeldt Y.

N Engl J Med. 2013 Jun 13;368(24):2329. doi: 10.1056/NEJMc1304815#SA2. No abstract available.

PMID:
23758242
4.

Extended anticoagulation in venous thromboembolism.

Franck AJ, Bovio JA.

N Engl J Med. 2013 Jun 13;368(24):2328-9. doi: 10.1056/NEJMc1304815#SA1. No abstract available.

PMID:
23758241
5.

Extended treatment of venous thromboembolism.

Connors JM.

N Engl J Med. 2013 Feb 21;368(8):767-9. doi: 10.1056/NEJMe1215678. No abstract available.

PMID:
23425170
6.

Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE.

Liem TK, DeLoughery TG.

Evid Based Med. 2014 Feb;19(1):29. doi: 10.1136/eb-2013-101317. Epub 2013 Jun 8. No abstract available.

PMID:
23749602
7.

Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.

Liem TK, Deloughery TG.

Semin Vasc Surg. 2011 Sep;24(3):157-61. doi: 10.1053/j.semvascsurg.2011.11.003. Review.

PMID:
22153026
8.

Warfarin or not.

Oliver M.

J R Coll Physicians Edinb. 2010 Dec;40(4):379; author reply 379-80. doi: 10.4997/JRCPE.2010.411. No abstract available.

PMID:
21132153
9.

Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.

Khemasuwan D, Suramaethakul N.

Clin Appl Thromb Hemost. 2012 Sep;18(5):476-86. doi: 10.1177/1076029612438957. Epub 2012 Mar 2. Review.

PMID:
22387584
10.

Direct oral anticoagulants for acute venous thromboembolism: closing the circle?

Verhamme P, Bounameaux H.

Circulation. 2014 Feb 18;129(7):725-7. doi: 10.1161/CIRCULATIONAHA.113.007478. Epub 2013 Dec 16. No abstract available.

11.

Treatment of venous thromboembolism with dabigatran.

Schulman S.

Curr Opin Pulm Med. 2012 Sep;18(5):410-5. doi: 10.1097/MCP.0b013e32835466eb. Review.

PMID:
22617811
12.

Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.

Atay JK, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):181-4. doi: 10.1177/1076029611416642. Epub 2011 Aug 25.

PMID:
21873358
13.

New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.

Aalbers J.

Cardiovasc J Afr. 2012 Oct;23(9):522. No abstract available.

14.

Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.

J Am Coll Cardiol. 2012 Sep 18;60(12):1118-9; author reply 1119-20. doi: 10.1016/j.jacc.2012.03.079. No abstract available.

15.

Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?

Knight BP.

J Am Coll Cardiol. 2012 Mar 27;59(13):1175-7. doi: 10.1016/j.jacc.2011.11.044. Epub 2012 Feb 1. No abstract available.

16.

Dabigatran versus warfarin for venous thromboembolism.

Teachey DT.

N Engl J Med. 2010 Mar 18;362(11):1050; author reply 1050-1. No abstract available.

PMID:
20301800
17.

Warfarin versus dabigatran: comparing the old with the new.

Abraham ME, Marcy TR.

Consult Pharm. 2012 Feb;27(2):121-4. doi: 10.4140/TCP.n.2012.121. Review.

PMID:
22330953
18.

A new era for anticoagulation in atrial fibrillation.

Mega JL.

N Engl J Med. 2011 Sep 15;365(11):1052-4. doi: 10.1056/NEJMe1109748. Epub 2011 Aug 27. No abstract available.

PMID:
21870977
19.

Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).

Prandoni P, Taher A.

Expert Opin Pharmacother. 2010 Apr;11(6):1035-7. doi: 10.1517/14656561003674397.

PMID:
20307227
20.

[New anticoagulants: dabigatran, rivaroxaban and apixaban].

Vargas Ruiz AG, Ramírez López AN, Medina Viramontes ME.

Gac Med Mex. 2012 May-Jun;148(3):257-64. Review. Spanish.

Supplemental Content

Support Center